Avadel Pharmaceuticals Gets Buyout Offer from Lundbeck

Avadel Pharmaceuticals receives a buyout offer from H. Lundbeck A.S., valuing the company at up to $23 per share. The offer includes $21 in cash and a potential $2 more per share based on drug sales. This comes after Avadel agreed to be acquired by Alkermes P.L.C. just weeks prior. Avadels board is considering Lundbecks offer, which they believe may be superior to the Alkermes deal.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.